Castle Wealth Management LLC Purchases 177 Shares of Amgen Inc. (NASDAQ:AMGN)

Castle Wealth Management LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 5.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,681 shares of the medical research company’s stock after purchasing an additional 177 shares during the period. Castle Wealth Management LLC’s holdings in Amgen were worth $959,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. AMF Tjanstepension AB increased its holdings in shares of Amgen by 16.9% in the third quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock worth $38,825,000 after buying an additional 17,387 shares during the period. Creative Planning increased its holdings in shares of Amgen by 8.6% in the third quarter. Creative Planning now owns 197,457 shares of the medical research company’s stock worth $63,402,000 after buying an additional 15,564 shares during the period. Swedbank AB increased its holdings in shares of Amgen by 1.1% in the third quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock worth $173,639,000 after buying an additional 5,751 shares during the period. Magnus Financial Group LLC increased its holdings in shares of Amgen by 15.2% in the third quarter. Magnus Financial Group LLC now owns 896 shares of the medical research company’s stock worth $289,000 after buying an additional 118 shares during the period. Finally, Regatta Capital Group LLC increased its holdings in shares of Amgen by 2.7% in the third quarter. Regatta Capital Group LLC now owns 6,083 shares of the medical research company’s stock worth $1,960,000 after buying an additional 159 shares during the period. Institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares of the company’s stock, valued at $8,496,669.44. The trade was a 46.35 % decrease in their position. The disclosure for this sale can be found here. 0.69% of the stock is currently owned by company insiders.

Amgen Price Performance

NASDAQ AMGN opened at $295.06 on Thursday. The business’s fifty day moving average price is $272.96 and its 200-day moving average price is $302.23. The stock has a market capitalization of $158.60 billion, a price-to-earnings ratio of 39.08, a PEG ratio of 3.01 and a beta of 0.56. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.96. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities analysts predict that Amgen Inc. will post 20.59 earnings per share for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.23%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio is 119.21%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on AMGN. Deutsche Bank Aktiengesellschaft decreased their price objective on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Royal Bank of Canada restated an “outperform” rating and set a $324.00 price target on shares of Amgen in a report on Friday, January 24th. Redburn Partners reduced their price target on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Truist Financial reduced their price target on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a report on Wednesday, January 8th. Finally, William Blair restated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $314.09.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.